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Conclusion: Patients with systemic sclerosis positive for anti-U1RNP dif-
fer in the predominance of inflammatory musculoskeletal manifestations and 
frequent combination with Sjogren’s syndrome and overlaps. Highly positiv-
ity for anti-U1RNP is accompanied by a persistent increase in RF, anti-Ro, 
anti-dsDNA
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Background: Seasonal patterns of disease onset and severity in idiopathic 
inflammatory myopathies (IIMs) as a whole are conflicting [1-3]. In recent 
years, over 10 myositis-specific antibodies (MSAs) have been identified. They 
are able to divide patients into homogenous subgroups and inform on prog-
nosis [4].
Objectives: The objective of the study was to investigate the seasonal variation 
of onset of IIMs characterised serologically.
Methods: This was a multi-centred retrospective observational study. Consec-
utive Chinese patients with IIMs admitted to the rheumatology wards of the 
participating major regional hospitals in Beijing and Hong Kong from July 2013 
to June 2018 were recruited. The diagnosis of IIMs was based on the Bohan 
and Peter’s criteria with definite or probable cases being included [5]. Patients 
with clinically amyopathic disease must have the typical Gottron’s papules 
or heliotrope rash as determined by rheumatologists or dermatologists, and 
with no symptoms or signs of muscle involvement according to Sontheimer 
[6]. Patients with juvenile myositis, inclusion body myositis, cancer-associated 
myositis and myositis associated with other connective tissue disease were 
excluded. A commercial line blot immunoassay kit (EUROLINE) was used to 
detect the MSAs.
Results: All together 495 patients were studied. The mean age of the patients 
at disease onset was 48.1 years (S.D. 13.3). There was a female predominance 
(68.3%). The subgroups of IIMs were: dermatomyositis (61.0%), polymyositis 
(21.8%), clinically amyopathic dermatomyositis (12.9%), immune mediated 
necrotising myopathy (3.8%) and nonspecific myositis (0.4%). No particular 
seasonal pattern in disease onset was observed in IIM patients as a whole (Fig-
ure 1) or in any classical subgroups. However, significantly more patients with 
any one MSA had their disease started in the first half of the year (p=0.007) as 
shown in Figure 2. Patients with either anti-synthetase or anti-MDA5 antibodies, 
which are associated with interstitial lung disease, had more frequent disease 
onset from November to February, which might coincide with the local flu sea-
son. It was also found that MSA positivity was associated with infection of the 
patient (p=0.005). Further analyses showed that patients with MSAs which are 
typically associated with severe skin disease (MDA5, TIF1g, NXP2, SAE) had 
more hospitalisation from April to September where excessive sun exposure is 
expected. There were no major differences between the Beijing and Hong Kong 
subgroups.
Conclusion: Apparent seasonal patterns were noticed in our ethno-serolog-
ically defined IIM patients. Certain environmental factors, particularly infection 
or UV exposure, could be potential triggers. Our findings could shed light on 
the identification of etiologic factors and enhance our understanding of disease 
pathogenesis. 
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Background: Systemic Sclerosis (SSc) is a rare and life-threatening connective 
tissue disease with multiple organ impairment. Cardio-pulmonary involvement is 
common: pulmonary fibrosis, pulmonary hypertension (PH), and electrical dis-
orders are the most serious complications and causes of increased mortality.
Objectives: We evaluated features related with the onset and development of 
PH in a cohort of SSc patients. We further studied ecocardiographic abnormali-
ties, by means of 2D-speckle tracking echocardiography (STE) with specific ref-
erence to the right ventricular strain measure (RV-strain).
Methods: We analyzed data from 50 SSc patients (pts) referred to our Univer-
sity-based Rheumatology Centre and SSc Unit from January 2007 to June 2019 
(F/M 45/5; lc/dcSSc 45/5; mean age 59.20±14.357 years; mean disease duration 
12.08±8.75 years). All pts underwent general and cardio-pulmonary assessment 
in our Cardio-Rheumatology Clinic. The following parameters were considered: 
blood exams, in particular inflammation indexes, uric acid test and serum autoan-
tibodies; pulmonary function tests; high resolution scan of the lungs (HRCT); 
standard electrocardiogram (ECG) and RV-strain measured by 2D-STE. These 
examinations were performed according to clinical picture and current methodol-
ogies. We compared SSc subjects with (10/50) and without (40/50) PH diagnosis 
during follow-up regardless of treatments.
Results: SSc pts with PH didn’t show significant alterations concerning RV-strain 
if compared with pts without PH (p=0.707). Nevertheless, RV-strain value was 
modified in relation to TAPSE alterations in all pts but this data correlated with right 
ventricular dilatation only in PH subjects. Furthermore, interesting significant val-
ues about dilatation of right and left atria (p=0.007, p=0.048), dilatation of inferior 
vena cava (p=0.037) and right ventricle (p=0.023) were observed. Left ventricular 
hypertrophy (p=0.012) as well as valvular insufficiencies (mitral and aortic) were 
more frequent in PH group too (p=0.016). These pts showed higher incidence of 
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skin ulcers (p=0.0001), higher values of blood pressure (p=0.004), elevated uric 
acid levels (p=0,027) and anti-centromere antibodies positivity (p=0.0001). 
Conclusion: Our research provides further evidence of the prognostic value 
of echocardiographic findings in SSc subjects, with focus on PH. Population 
enlargement is ongoing in order to identify more accurate results about RV-strain, 
considering the efficacy of PH treatments on cardiac contractility. Speckle track-
ing echocardiography proves to be a sensitive, low-cost, non-invasive and reliable 
tool to detect early cardiac impairment in Ssc, full of potential future prospects.
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Background: Nailfold capillary abnormalities are one of representative signs in 
systemic sclerosis (SSc). However, previous reports about changes in nailfold 
capillary by immunosuppressive therapy have been limited. Especially, there have 
been no reports about short-term changes in nailfold capillary abnormalities.
Objectives: To clarify whether intravenous cyclophosphamide (IVCY) treatment 
for SSc patients can improve nailfold capillary abnormalities in half a year.
Methods: Among patients diagnosed as having SSc according to the 2013 ACR/
EULAR classification criteria at our hospital from May 2018 to December 2019, 
those who treated with IVCY for interstitial lung disease (ILD) were consecutively 
registered. All patients received IVCY six times. Nailfold capillary abnormalities on 
eight fingers including both second to the fifth fingers were observed with a nailfold 
videocapillaroscopy (NVC). Each finger was evaluated for enlarged capillary, giant 
capillaries, hemorrhage, loss of capillary, disorganization of the vascular array, and 
capillary ramification. Quantitative scoring was performed on a scale of 0 to 3 in 
accordance with the ratio of each of them. NVC tests were evaluated before IVCY 
treatment intervention and after IVCY. In all cases, the evaluation of NVC after IVCY 
treatment was performed 6 months after the administration day. Skin changes were 
evaluated by modified Rodnan’s total skin thickness score (mRSS) at performing 
NVC. Anti-centromere antibodies, anti-Scl-70 antibodies, anti-RNA polymerase III, 
and anti-RNP antibodies were measured. Pulmonary function tests (PFTs) includ-
ing forced vital capacity (FVC) and diffusing capacity of the lung carbon monoxide 
(DL
CO
) were performed before and after IVCY. The statistical significance of the 
differences between means of two groups was evaluated by paired t-test. A p level 
of 0.05 or less was considered statistically significant.
Results: Five patients were included. The mean age was 59 years and 4 patients 
were female (80%). High dose corticosteroids were used in 2 patients (40%). Anti-
RNA polymerase III was positive in 2 patients (40%), anti-Scl-70 antibody was posi-
tive in 1 (20%), and negative test for any specific antibodies was in 2 (40%). Changes 
in NVC scores, which were total scores of 8 fingers, were as follows: Enlarged; 
13.2±4.8 to 6.4±5.9 (p=0.018), Giant; 7.0±5.7 to 1.6±1.1 (p=0.0314), Hemorrhage; 
8.4±6.2 to 3.2±2.3 (p=0.0274), Loss; 4.0±2.5 to 0.6±1.3 (p=0.0288), Disorganization; 
0.6±0.9 to 1.0±1.0 (p=0.7065), Ramification; 0.6±0.9 to 0.8±1.8 (p=0.5730). (Table) 
After IVCY treatment, mRSS reduced in 4 cases (80%). Changes in mRSS scores 
were as follows: 18.8±8.3 to 12.4±13.3 (p=0.0677). The cases with improved mRSS 
and those with improved NVC findings were consistent. The mean FVC before and 
after IVCY was 2077 ml and 2062 ml, respectively. The mean DL
CO
 before and after 
IVCY was 9.88 mL/min/mmHg and 9.58 mL/min/mmHg, respectively.
Conclusion: Nailfold capillary abnormalities in patients with SSc could be 
improved in half a year with IVCY. Especially, early phase elements including 
enlargement, giant, and hemorrhage were specifically reversible.
Table.  
No. (E) (G) (H) (L) (D) (R) mRSS
1 21→14 16→3 19→7 0→0 0→2 0→0 14→9
2 12→3 4→2 6→1 4→0 2→1 1→0 15→1
3 14→11 8→2 6→2 7→0 0→0 0→4 10→5
4 10→4 6→1 8→3 4→3 0→2 2→0 25→12
5 9→0 1→0 3→3 5→0 1→0 0→0 30→35
mean ± SD 13.2±4.8 7.0±5.7 8.4±6.2 4.0±2.5 0.6±0.9 0.6±0.9 18.8±8.3
6.4±5.9 1.6±1.1 3.2±2.3 0.6±1.3 1.0±1.0 0.8±1.8 12.4±13.3
p-value 0.018 0.0314 0.0274 0.0288 0.7065 0.5730 0.0677
E: enlarged, G: giant, H: hemorrhage, L: loss, D: disorganization, R: ramification.
The table shows the total of eight points for each finding in the NVC test. The previously 
described values are before treatment and the later values are after treatment.
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Background: Systemic sclerosis (SSc), a chronic autoimmune disease, is asso-
ciated with autonomic neuropathy1. Autonomic neuropathy, especially cardiovas-
cular autonomic neuropathy (CAN) is significant risk predictor of sudden cardiac 
death. However, its relationship with disease specific measures remains unex-
plored in SSc.
Objectives: To assess cardiovascular autonomic neuropathy and sudomotor 
function and its predictors in systemic sclerosis.
Methods: In this cross-sectional study, 16 SSc patients meeting the 2013 
European League Against Rheumatism (EULAR) and American College of 
Rheumatology (ACR) classification criteria and 15 age and sex-matched 
healthy controls were recruited. Cardiovascular autonomic function assessed 
by five cardiovascular reflex tests according to Ewing. Peripheral sympa-
thetic autonomic function assessed by FDA approved Sudoscan (Impeto 
Medical, Paris) through measurement of electrochemical skin conductance. 
Disease-specific measures (Disease duration, Modified Rodnan Skin Score 
(mRSS), EUSTAR activity score), and inflammatory measures (ESR, CRP) 
were determined. Quality of life measured by Scleroderma Health Assess-
ment Questionnaire (SHAQ).
Results: Systemic sclerosis patients had significantly impaired parasym-
pathetic [Heart rate response to deep breath (HRD) (Fig.  1A), Heart rate 
response to standing (HRS) (Fig.  1B) and Heart rate response to valsalva 
manoeuvre (Fig.  1C)] and symapathetic [BP response to hand grip (BPH) 
(Fig. 1D)] function as compared to healthy controls. Scleroderma patients had 
significantly impaired sudomotor function (p<0.05) as compared to healthy 
controls. Levels of mRSS, EUSTAR score, ESR, CRP and SHAQ were sig-
nificantly higher in SSc patients as compared to healthy controls (p≤0.05). 
Parasympathetic (HRD & HRS) dysfunction inversely correlated with ESR, 
CRP and mRSS. Sudomotor function positively correlated with mRSS, dis-
ease duration and CRP.
Conclusion: CAN and Sudomotor function are significantly impaired in SSc. 
Parasympathetic dysfunction is more pronounced than sympathetic dysfunction 
in SSc. CAN and Sudomotor dysfunction are associated with disease-duration, 
skin-score, ESR and CRP. These could serve as potential predictors of Cardio-
vascular Autonomic neuropathy and sudomotor dysfunction in SSc. 
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